Know Cancer

forgot password

Phase I/II Cellular Immunotherapy Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer

Phase 1/Phase 2
18 Years
85 Years
Open (Enrolling)
Breast Cancer

Thank you

Trial Information

Phase I/II Cellular Immunotherapy Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer

Inclusion Criteria:

- Stage IV histologically proven breast cancer as defined by the AJCC Cancer

- Staging Manual (6th edition 2003)

- Patients must have completed one prior form of chemo and or radiation therapy for
their disease and have failed to achieve remission.

- There must be no clinical or radiographic signs of active brain metastases (CT of
brain), or disease to the brain that is not considered controlled.

- At least 4 weeks must have elapsed since chemotherapy or biological therapy and 2
weeks must have elapsed since therapy.

- Female patients must be at least 18 years of age

- Must be ambulatory with a ECOG performance status of <2

- Must have common recall antigen DTH skin >2mm

- Must have lab values as following ANC >1.5 x 109/L; platelets >100x109/L; Hb>9g/dL;
creatinine<1.8 mg/dL or a creatinine clearance > 35 mL/min; total bilirubin < 2 x the
upper limit of normal; AST and ALT < 2.5 x the upper limit of normal; albumin > 2.5

- If of child bearing potential, must practice a reliable method of contraception at
screening and must agree to continue this status until 6 months after receiving the
last study vaccine injection. An HCG (pregnancy) test will be done monthly until the
3 vaccinations are complete.

- Signed informed consent (see Appendix A, Clinical Protocol section 25.1) to be
obtained according to ICH GCP guidelines before the patient is subjected to any extra
diagnostic procedures performed for evaluation of eligibility for the trial.

Exclusion Criteria:

- History of prior malignancy, with the exception of curatively treated basal cell or
squamous cell carcinoma of the skin or cervical cancer stage 1B

- Active infection requiring continuous use of antibiotic therapy

- Significant cardiac or other medical illness that would limit activity or survival,
such as severe congestive heart failure, unstable angina, or serious cardiac

- Autoimmune disease currently treated with steroids

- Adverse reactions to vaccines such as anaphylaxis or other serious reactions, e.g.
life-threatening reactions to medicine

- History of immunodeficiency or autoimmune disease such as rheumatoid arthritis,
systemic lupus erythematosus, scleroderma, polymyositis dermatomyositis, juvenile
onset insulin dependent diabetes, or a vasculitic syndrome

- Pregnancy or lactation

- Any reason why, in the opinion of the investigator, the patient should not

- Patients who have received cytotoxic anti-tumor therapy within 4 weeks prior to

- Patients with active hepatitis (B,C) or HIV + individuals

- Patients with more than four different lines of chemotherapy in the metastatic
setting (excluding adjuvant chemotherapy)

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:


Outcome Time Frame:

24 months

Safety Issue:


Principal Investigator

Paul O. Schwarzenberger, M.D.

Investigator Role:

Principal Investigator


United States: Food and Drug Administration

Study ID:




Start Date:

May 2008

Completion Date:

September 2011

Related Keywords:

  • Breast Cancer
  • Stage IV histologically proven breast cancer
  • Breast Neoplasms



Quantum Immunologics, Inc.Mobile, Alabama  36608